Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

We apologize for any inconvenience, but the press release has been removed from the website. This action was taken due to either receiving a complaint or at the request of the distribution agency. If you suspect there may have been an error, kindly reach out to our administrator for further assistance. Thank you for your understanding.

Market Details

Copyright © 2024 | All rights reserved